{"prompt": "['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', 'If continued participation in the trial, e.g. because of any clinical adverse event, laboratory', 'abnormality, or other medical condition or situation would not be in the best interest of the', 'subject', 'If the subject meets an exclusion criterion (either newly developed or not previously recognized)', 'that precludes further study participation, e.g. elevated TSH indicating hypothyroidism', 'If the subject is unable to receive study drug for the prescribed duration, and/or complete it.', 'The date and specific reason for participant discontinuation or withdrawal from the study will be recorded', 'on a separate Case Report Form. Subjects who sign the informed consent form and are randomized but', 'do not receive the study intervention may be replaced. Subjects who sign the informed consent form,', 'and are randomized and receive the study intervention, and subsequently withdraw, or are withdrawn or', 'discontinued from the study may also be replaced. It is anticipated that up to 10% (6) subjects will', 'discontinue or drop out of the trial; thus, 66 subjects will be enrolled to assure 60 subjects complete it.', '7.3 LOST TO FOLLOW-UP', 'Lost to Follow-up. Study subjects will be followed for a total of 24 weeks during the trial. Validity of the', 'study is at risk when subjects are lost to follow-up, as information for endpoint documentation and', 'evaluation is then lost. A study subject will be considered lost to follow-up if she fails to return for a', 'scheduled visit and is unable to be contacted by the study site staff.', 'The following actions must be taken if a participant fails to return for a required study visit:', 'The site will attempt to contact the participant and reschedule the missed visit within 4 weeks', 'and counsel the participant on the importance of maintaining the assigned visit schedule and', 'ascertain if she wishes to and/or should continue in the study.', 'Before a subject is deemed lost to follow-up, the investigator will make every effort to regain', 'contact with the subject, including up to 3 telephone calls and, if necessary, a certified letter to', \"the subject's last known mailing address or local equivalent methods. These contact attempts will\", \"be documented in the subject's study file.\", 'Should the subject continue to be unreachable, she will be considered to have withdrawn from', 'the study with a primary reason of lost to follow-up.', '8', 'STUDY ASSESSMENTS AND PROCEDURES', '8.1', 'EFFICACY ASSESSMENTS', 'This section includes a list and description of the efficacy assessments to be conducted on the', 'trial.', 'PBAC Score. The PBAC will be scored for the 2 previous menstrual cycles and as the primary', 'efficacy outcome of the trial for each cycle on the trial. PBAC at screening will be scored by the', 'subject to determine eligibility, which per definition of menorrhagia, requires the PBAC score be', '23']['The VWDMin Trial', 'Version v1.0', 'Protocol PRO15070638', 'March 19, 2018', '>100 for at least one of two previous menstrual cycles. If the PBAC is not above 100 in past two', 'cycles, this constitutes exclusion from participation. PBAC for each cycle, including Cycle 1 and 2', 'on study drug (either rVWF or TA) will be compared to PBAC for cycles 3 and 4 on study drug', '(either TA or rVWF).', 'Cycle Severity Rating (CSR) and Cycle Length (CL). The cycle severity (CS) and cycle duration', '(CSL) will be rated by numeric scale 0-3, and recorded in diaries. This will rate the severity of', 'each cycle by a single score: ratings include: 0=mild bleeding much less than usually', 'experienced; 1=moderate bleeding less than usually experienced; 2=moderately severe bleeding', 'but not as bad as the worst menstrual bleeding experienced; and 3=severe bleeding, as bad as', 'the worst menstrual bleeding experienced. Cycle length (CL) will be in days of tampon/pad use', 'on PBAC. These measures will provide more subjective ratings than PBAC, and as such, will', 'provide distinct data separate from the primary endpoint.', 'Quality-of-Life Questionnaires. The impact of the two study interventions on quality of life will', 'be determined by SF-36, Ruta Menorrhagia Severity Score, CDC-HRQoL-14, and CES-D,', 'measured at baseline, and after the first two cycles (Visit 3), and after the second two cycles', '(Visit 4). The Short-Form-36 (SF-36) is a 36-item general health survey in eight areas of physical', 'and mental health (67,68), which has been validated in women of reproductive age and strongly', 'associated with VWD phenotype: lower SF-36 scores correlate with higher bleeding scores (69).', 'The Ruta Menorrhagia Severity Scale is a 15-item instrument that measures the physical,', 'psychological and social effects of menorrhagia (70), and is validated for menorrhagia: higher', 'scores correlate with reduced PBAC (13). The CDC Health-Related Quality of Life (HRQoL-14) is', 'a 14-item instrument that assesses \"healthy days\" including the number of physically and', 'mentally unhealthy days in the past 30 days, and has been standardized for women of', 'reproductive age (71). The Center for Epidemiology Studies Depression (CES-D) Scale is a 20-', 'item screen for depression that identifies depression symptoms over a range of ages and', 'demographic groups (72). It is expected that QoL score by these 4 scales will improve with study', 'drugs and correlate with the reduction in menorrhagia by PBAC score.', 'Satisfaction Survey. A Satisfaction Survey will be assessed after two cycles of rVWF in which', 'subjects will a) rate treatment with rVWF as compared with their usual treatment of heavy', 'menses; b) rate how difficult or problematic the use of rVWF was; and c) indicate if rVWF will be', 'considered for use in future menstrual cycles. It is anticipated that if rVWF results in no better', 'improvement than TA, satisfaction will be lower, and the use of rVWF may not be justified.', 'Cost-Effectiveness Questionnaire. Given rWF burden (IV route, cost), we will collect cost-', 'effectiveness data (i.e. days lost from work/school, and need for iron infusion, RBC transfusion,', 'or ER or hospital care) and compare events prevented and cost savings after 2 cycles on each', 'treatment. Intervention and event costs will be estimated using data for Centers for Medicare', 'and Medicaid Services (CMMS) and Healthcare Cost Utilization Project (HCUP) (73). The', 'effectiveness term in the analyses will be intervention-specific SF-36 QoL utility values (74). Data', 'will also be compared by general estimating equations (75), which may be underpowered by the', 'small sample size and short trial follow-up (76), and thus, will be an exploratory endpoint.', 'Please refer to MOP for detailed description of study procedures.', '24']\n\n###\n\n", "completion": "END"}